We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
While retail prices for cancer drugs may be the highest in the U.S., these medicines appear to be less affordable in poorer countries such as India and China despite their lower prices, according to a study. Read More
Despite the FDA extending the comment period for its recommendations on biosimilar labeling, several industry groups have still made public their concerns about the draft guidance. Read More
To drive the development of advanced therapies, industry is asking the European Medicines Agency to provide further guidance, harmonize EU regulations and exercise flexibility. Read More
Vermont Gov. Peter Shumlin signed into law Friday a transparency bill that would require certain drugmakers to justify their price increases for specific products. Read More